Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
111. |
ECCT/19/02/01 | DANCE Study An Open-Label, Single Arm Study to Evaluate the Week 48 Efficacy and Safety of a Two-Drug Regimen of Dolutegravir/Lamivudine (DTG/3TC) as a Fixed Dose Combination (FDC), in Antiretroviral Therapy (ART)-Naive HIV-1-Infected Adolescents, ≥12 To <18 Years of Age who Weigh at Least 40 Kg. |
Principal Investigator(s) 1. Fredrick Odhiambo Otieno 2. Isaac Tsikhutsu Site(s) in Kenya 1. Nyanza Reproductive Health Society (Kisumu county) 2. Kenya Medical Research Institute (Kisumu county) 3. Kenya Medical Research Institute, Walter Reed Project (Kericho county) |
View |
112. |
ECCT/21/07/01 | RESOLVE A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell DiseaseA Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell Disease |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Jessie Nyokabi Githanga Site(s) in Kenya 1. Strathmore University Medical Center (Nairobi City county) 2. KEMRI Kondele children\'S Hospital (Kisumu county) 3. Gertrude\'s Children\'s Hospital (Nairobi City county) |
View |
113. |
ECCT/22/05/01 | VICTORION-2 PREVENT A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease |
Principal Investigator(s) 1. Anthony Gikonyo 2. ELIJAH SAMMY NYAINDA OGOLA Site(s) in Kenya 1. The Karen Hospital (Nairobi City county) 2. Centre for research in Therapeutic Sciences (CREATES (Nairobi City county) |
View |
114. |
ECCT/22/05/02 | BREATHER Plus A randomised open-label 2-arm, 96-week trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily dolutegravir/tenofovir-based triple ART in virologically suppressed HIV-infected adolescents aged 12 to 19 years of age in sub-Saharan Africa |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya Moi University Clinical Research Centre |
View |
115. |
ECCT/23/05/07 | LATA Long-Acting Treatment in Adolescents (LATA) A randomised open-label 2-arm 96 week trial in virologically suppressed HIV-1-positive adolescents aged 12-19 years of age in Sub-Saharan Africa |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. |
View |